Marizomib: Interim Phase I data

Interim data from 12 evaluable patients with grade IV malignant glioma in an open-label, dose-escalation, North

Read the full 161 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE